Press Releases

Date Title
Toggle Summary Kura Oncology to Participate in the Leerink Global Healthcare Conference
LA JOLLA, Calif. , Feb. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at 2:15 p.m. ET ( 11:15 a.m.
Toggle Summary Kura Oncology Announces Data Presentation on Lead Product Candidate Tipifarnib at the Upcoming ASH Meeting
Tipifarnib as Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients With High Risk Disease LA JOLLA, Calif. , Dec. 3, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that new data from
Toggle Summary Kura Oncology to Present at the Oppenheimer 2015 Healthcare Conference
LA JOLLA, Calif. , Dec. 1, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 10:55 a.m. EST ( 7:55 a.m.
Toggle Summary Kura Oncology to Present at Upcoming Investor Conference
LA JOLLA, Calif. , Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 11:30 a.m. EST ( 8:30 a.m.
Toggle Summary Kura Oncology Announces First Patient Dosed in an Investigator-Sponsored Phase 2 Trial of Tipifarnib in Patients With HRAS Mutant Urothelial Cancer
LA JOLLA, Calif. , Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), today announced that the first patient has been dosed in an investigator-sponsored Phase 2 trial of its lead drug candidate, tipifarnib, an inhibitor of protein farnesylation, in cancer patients with urothelial
Toggle Summary Kura Oncology to Present at the Jefferies 2015 Global Healthcare Conference
LA JOLLA, Calif. , Nov. 11, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 2:40 p.m. GMT ( 6:40 a.m.
Toggle Summary Kura Oncology Announces Pricing of Public Offering of Common Stock
LA JOLLA, Calif. , Nov. 4, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced the pricing of its public offering of 6,250,000 shares of common
Toggle Summary Kura Oncology Announces Launch of Public Offering of Common Stock
LA JOLLA, Calif. , Oct. 28, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced that it has commenced an underwritten public offering of
Toggle Summary Kura Oncology Appoints Thomas Malley to Board of Directors
LA JOLLA, Calif. , Oct. 14, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company, today announced the appointment of Thomas Malley to its board of directors. "Tom has extensive knowledge and understanding of the healthcare industry," said Troy Wilson
Toggle Summary Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma
Second of Two Planned Company Sponsored Phase 2 Trials for Tipifarnib LA JOLLA, Calif. , Sept. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers,